Glenmark Pharma is concluding the final phase of its marketing approval application process to launch its nasal spray Ryaltris in 17 countries in the European Union, the pharma giant said on Monday.
The company further said that the spray is now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age.
The spray is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.
